, Columnist
Biogen Has More Hope Than Data for Alzheimer’s Drug
The evidence that its treatment works is more confusing than convincing.
Photographer: Dominick Reuter/AFP/Getty Images
This article is for subscribers only.
No drug for Alzheimer’s disease does anything but treat symptoms of the degenerative ailment. The first medicine that can do more will be an enormous breakthrough.
Biogen Inc. thinks it has that drug in aducanumab. It’s a treatment the company previously announced was a failure in March, but in a highly unusual move, it is trying to resurrect the medicine and gambling that it can win Food and Drug Administration approval. The company presented an expanded case for the medication at a medical meeting on Thursday.